Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

May 13, 2020

Conditions
Rheumatoid Arthritis RA
Interventions
DRUG

Efavaleukin alfa

Efavaleukin alfa administered as a subcutaneous injection.

DRUG

Placebo

Placebo administered as a subcutaneous injection.

Trial Locations (15)

1612

Research Site, Sofia

10117

Research Site, Berlin

15006

Research Site, A Coruña

16635

Research Site, Duncansville

36207

Research Site, Anniston

48910

Research Site, Lansing

60590

Research Site, Frankfurt am Main

75231

Research Site, Dallas

90502

Research Site, Torrance

05-410

Research Site, Józefów

30-348

Research Site, Krakow

60-848

Research Site, Poznan

37-450

Research Site, Stalowa Wola

21-040

Research Site, Świdnik

51-128

Research Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY